Overall, our results show that CD38 level affects the anti-MM activity of NAD+-depleting agents and that hijacking CD38-NAD+ase activity would represent an innovative strategy to sensitize MM cells to these drugs. The gene discussed is CD38; the disease is Miyoshi myopathy.